Ganciclovir treatment of symptomatic congenital cytomegalovirus infection: Results of a phase II study

Journal of Infectious Diseases

Volumn 175, Issue 5, 1997, Pages 1080-1086

  Whitley, Richard J ^a   Cloud, Gretchen ^b   Gruber, William ^b   Storch, Gregory A ^b   Demmler, Gail J ^b   Jacobs, Richard F ^b   Dankner, Wayne ^b   Spector, Stephen A ^b   Starr, Stuart ^b   Pass, Robert F ^b   Stagno, Sergio ^b   Britt, William J ^b   Alford Jr , Charles ^b   Soong, Seng Jaw ^b   Zhou, Xiao Jian ^b   Sherrill, Lanette ^b   FitzGerald, Jan M ^b   Sommadossi, Jean Pierre ^b  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

GANCICLOVIR;

ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONGENITAL INFECTION; CYTOMEGALOVIRUS INFECTION; DRUG BLOOD LEVEL; DRUG URINE LEVEL; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; NEUTROPENIA; NEWBORN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 16944362657     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/516445     Document Type: Article

References (19)

1. Alford CA Jr. Chronic congenital infections of man. Yale J Biol Med 1982;55:187-92.
2. Alford CA, Stagno S, Pass RF, Huang ES. Epidemiology of cytomegalovirus. In: Nahmias A, Dowdle W, Schinazi R, eds. The human herpesviruses: an interdisciplinary perspective. New York: Elsevier, 1981:159-71.
3. Stagno S, Cloud GA. Changes in the epidemiology of cytomegalovirus. In: Lopez C, ed. Immunobiology and prophylaxis of human herpesvirus infections. New York: Plenum Press. 1990:93-104.
4. Stagno S, Pass RF, Dworsky ME, et al. Congenital cytomegalovirus infection: the relative importance of primary and recurrent maternal infection. N Engl J Med 1982;306:945-9.
5. Hanshaw JB. Congenital cytomegalovirus infection: a fifteen year perspective. J Infect Dis 1971;123:555-61.
6. McCracken GJ Jr, Shinefield HR, Cobb K, Rausen AR, Dische MR, Eichenwald HF. Congenital cytomegalic inclusion disease. A longitudinal study of 20 patients. Am J Dis Child 1969;117:522-39.
7. Pass RF, Stagno S, Myers GJ, Alford CA. Outcome of symptomatic congenital CMV infection: results of long-term longitudinal follow-up. Pediatrics 1980;66:758-62.
8. Weller TU. The cytomegaloviruses: ubiquitous agents with protean clinical manifestations. N Engl J Med 1971;285:203-14, 267-74.
9. Weller TH, Hanshaw JB. Virologic and clinical observations on cytomegalic inclusion disease. N Engl J Med 1962;266:1233-44.
10. Trang JM, Kidd L, Gruber W, et al. Linear single-dose pharmacokinetics of ganciclovir in newborns with congenital cytomegalovirus infections. Clin Pharmacol Ther 1993;53:15-21.
11. Zhou XJ, Gruber W, Demmler G, et al. Population pharmacokinetics of ganciclovir in newborns with congenital cytomegalovirus infections. Antimicrob Agents Chemother 1996;40:2202-5.
12. Whitley RJ, Connell J, Markiewicz MA, Sommadossi JP. Novel pharmacological strategies in the treatment of life-threatening cytomegalovirus infections: clinical experience with continuous infusion (9-(1,3-dihydroxy-2-propoxymethyl) guanine. Ann NY Acad Sci 1990;616:452-60.
13. Institute of Medicine, Committee to Review the Fialuridine (FIAU/FIAC) Clinical Trials. Review of the fialuridine (FIAU) clinical trials. In: Manning FJ, Swartz M, eds. Washington, DC: National Academy Press. 1995:
14. Hutto SC, Ricks R, Garvie M, Pass RF. Epidemiology of cytomegalovirus infections in young children: day care vs. home care. Pediatr Infect Dis 1985;4:149-52.
15. Pass RF, Hutto SC, Ricks R, Cloud GA. Increased rate of cytomegalovirus infection among parents of children attending day care centers. N Engl J Med 1986;314:1414-8.
16. Alford CA Jr, Britt WJ. Cytomegalovirus. In: Roizman B, Whitley RJ, Lopez C, eds. The human herpesviruses. New York: Raven Press. 1993:227-55.
17. Buhles WC Jr, Mastre BJ, Tinker AJ, Strand V, Koretz SH, the Syntex Collaborative Ganciclovir Treatment Study Group. Ganciclovir treatment of life- or sight-threatening cytomegalovirus infection: experience in 314 immunocompromised patients. Rev Infect Dis 1988;10:495-504.
18. Fowler KB, Stagno S, Pass RF, Britt WJ, Boll TJ, Alford CA. The outcome of congenital cytomegalovirus infection in relation to maternal antibody status. N Engl J Med 1992;326:663-7.
19. Nigro G, Scholz H, Bartmann U. Ganciclovir therapy for symptomatic congenital cytomegalovirus infection in infants: a two-regimen experience. J Pediatr 1994;124:318-22.